Please assess the completion status of the following clinical trial:

Trial Title: Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years at the time of dalbavancin treatment initiation~* Male and female patients~* Patients who received dalbavancin as targeted or empirical therapy to treat Gram-positive bacterial infection or as anti-Gram-positive component of a treatment regimen for mixed infection (e.g., with concurrent antibacterial or antifungals drugs for covering Gram-negative strains or fungi)~* Patients who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study~* Patients with known type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) at the time of infectious disease of interest diagnosis~* Patients with available retrospective data in medical charts, including information about dalbavancin treatment and diabetes history~* Patients who gave informed consent and personal data processing consent to take part into the study following local regulation.~Exclusion Criteria:~* Patients enrolled in a clinical trial in which treatment with dalbavancin was managed through a study protocol~* Patients diagnosed with any hyperglycemic state other than T1DM or T2DM at the time of dalbavancin treatment initiation~* Patients with long-term infection (over than 12 months of duration) at the time of dalbavancin treatment initiation~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Pregnant or breast-feeding patients from start time of dalbavancin treatment initiation till enrolment visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).